top stories

Supreme Court weighs in on Pur­due Phar­ma's bank­rupt­cy, with an eye to­ward opi­oid vic­tims

6 hours ago
Law

House com­mit­tee in­ves­ti­gates FDA’s han­dling of com­mon nasal de­con­ges­tant as ef­fi­ca­cy ques­tions loom

9 hours ago
Pharma
FDA+

Health in­sur­ance mem­bers stand to lose out if Cigna and Hu­mana fi­nal­ize a megamerg­er, ex­perts say

7 hours ago
Health Tech

Al­to Neu­ro­science un­veils ef­fi­ca­cy sig­nal from PhI­Ia MDD tri­al with ma­chine learn­ing-iden­ti­fied bio­mark­er

3 hours ago
R&D

Latest

23andMe said hack­ers ac­cessed over five mil­lion mem­bers’ an­ces­try in­fo

4 hours ago
Health Tech

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

5 hours ago
Pharma
FDA+

En­do hits the pool hall with Pey­ronie’s dis­ease pa­tients for lat­est cam­paign

5 hours ago
Marketing

Fu­ji­film makes $200M man­u­fac­tur­ing in­vest­ment while No­var­tis pours $80M+ in­to Chi­na fa­cil­i­ty

6 hours ago
Pharma
Manufacturing

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

9 hours ago
R&D

Ideaya part­ners with Gilead; Lil­ly ex­tends of­fer for Point; The­seus lets go of CEO, CMO

9 hours ago
News Briefing
see latest stream
People

Or­na Ther­a­peu­tics trims staff in ‘de­fen­sive re­duc­tion’ de­spite large fi­nanc­ing hauls

4 days ago

Gilead­'s cell ther­a­py busi­ness Kite cuts 7% of work­force

5 days ago

Gen­er­a­tion Bio to lay off 68 em­ploy­ees in a dif­fi­cult year for non-vi­ral gene ther­a­py biotechs

5 days ago
Financing

Seis­mic rais­es $121M to en­ter im­munol­o­gy space spot­light­ed by ar­genx, Im­muno­vant and oth­ers

13 hours ago

Ex­clu­sive: San Diego biotech rais­es $11.7M to use cells as tar­get­ed de­liv­ery ves­sels for ge­net­ic med­i­cines

3 days ago

ARCH-al­lied AN Ven­ture Part­ners rais­es $200M to build biotechs out of re­search from Japan

3 days ago
Startups

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug ...

4 days ago

Neu­ro start­up stock craters af­ter PhI­II study marred with ‘sig­nif­i­cant de­vi­a­tion’ from tri­al pro­to­col

5 days ago

Flag­ship opens hub, plants roots in the UK as gov­ern­ment aims to boost life sci­ence ecosys­tem

6 days ago
Deals

Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

10 hours ago

As­traZeneca inks $247M deal with gen­er­a­tive AI shop Ab­sci to de­vel­op an­ti­body drug for can­cer

13 hours ago

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

16 hours ago

In FocusSee all

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

4 weeks ago
R&D
Discovery

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

4 weeks ago
Cell/Gene Tx

Ra­dio­phar­ma CD­MOs nav­i­gate sup­ply chain, raw ma­te­r­i­al chal­lenges as de­mand goes nu­clear

Last month
Manufacturing

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last month
R&D
Pharma

Endpoints Standouts

A con­ver­sa­tion with No­bel Prize win­ner Katal­in Karikó on re­jec­tion, fi­nal­ly be­ing rec­og­nized and her mR­NA work

2 months ago
People

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

Last month
AI
In Focus

How No­vo Nordisk’s Ry­bel­sus went from pan­dem­ic washout to block­buster, and what’s next for oral weight loss

Last month
Pharma
Marketing

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last month
R&D
In Focus

Peer review See all

Dec
1

Amy­lyx hires new CMO from Ul­tragenyx; Eliot Forster is back as a CEO af­ter F-star sale

Nov
17

De­sign Ther­a­peu­tics hints at ‘strate­gic re­align­ment,’ re­places CEO; Karyopharm co-founder leads AT­P's Nereid

Nov
10

Cen­tu­ry Ther­a­peu­tics nabs Bris­tol My­ers alum as CEO; En­her­tu star Dai­ichi Sankyo makes changes in Eu­rope

Nov
3

CNS biotech Rap­port snags a CFO vet­er­an from Karuna; Bris­tol My­ers’ new CEO to chair the board next year

Oct
27

Flag­ship's Mon­tai Health hires first CMO; Fi­nance leader to re­tire at J&J part­ner Xen­cor

Pharma channel feed

15 hours ago

FDA ap­proves Lil­ly’s BTK in­hibitor Jaypir­ca for two more blood can­cers

The FDA grant­ed ac­cel­er­at­ed ap­proval to Eli Lil­ly's Jaypir­ca for cer­tain pa­tients with chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, the In­di­anapo­lis-based phar­ma com­pa­ny ...

READ MORE

Sam­sung Bioepis strikes deal for Ste­lara biosim­i­lar, but launch like­ly won't come in time for an IRA ex­emp­tion

3 days ago
FDA+

EMA sends more ques­tions to GLP-1 mak­ers over pos­si­ble risk of sui­cide, self-harm

3 days ago
latest in Pharma

As­traZeneca halts two PhI­II hy­per­kalemia stud­ies in­tend­ed to spot­light Lokel­ma’s clin­i­cal val­ue

3 days ago

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

4 days ago
Deals

No­vo Nordisk ramps up le­gal case against com­pound­ing phar­ma­cies sell­ing 'mis­brand­ed' semaglu­tide

4 days ago
Law

FDA ships Form 483 to gener­ic drug gi­ant Dr. Red­dy’s due to equip­ment is­sues, oth­er ob­ser­va­tions

4 days ago
FDA+
Manufacturing

GSK is win­ning 70% of the RSV mar­ket, while Pfiz­er's launch has left it ‘dis­ap­point­ed’ so far

4 days ago
see latest stories

Marketing channel feed

13 hours ago

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

The new No­var­tis — with the gener­ics and biosim­i­lar busi­ness San­doz spun out along with a strate­gi­cal­ly culled drug pipeline — is kick­ing off its next chap­ter with a new brand iden­ti­ty ...

READ MORE

Pfiz­er, Idor­sia and Ab­b­Vie drug brands lead the way in phar­ma dig­i­tal mar­ket­ing — study

3 days ago

No­var­tis taps ‘So­pra­nos’ ac­tress for new mul­ti­ple scle­ro­sis Kes­imp­ta cam­paign

3 days ago
Pharma
latest in Marketing

Ot­su­ka am­pli­fies re­search-based men­tal health pro­gram, adds first dig­i­tal ac­cess

3 days ago
Pharma

Drug prices in TV ads again? Sen­a­tors take an­oth­er swing with ex­pe­dit­ed bill

4 days ago
Pharma

Mar­ket­ingRx roundup: Pfiz­er adds hol­i­day twist to Covid boost­er ef­fort; No­vavax signs up for sports

6 days ago
Pharma

Take­da aligns with lead­ing rare dis­ease group for calls to ac­tion around health eq­ui­ty di­ag­noses

6 days ago
Pharma

Who cares about phar­ma ESG ef­forts? Pa­tients and pa­tient groups do — and they want more, sur­vey finds

6 days ago
Pharma
see latest stories

FDA+ channel feed

3 days ago

Apel­lis' eye dis­ease drug gets safe­ty la­bel up­date for rare in­flam­ma­tion side ef­fect

The FDA and Apel­lis Phar­ma­ceu­ti­cals have up­dat­ed the la­bel for Syfovre — an in­jec­tion for late-stage wet age-re­lat­ed mac­u­lar de­gen­er­a­tion — to ad­dress the po­ten­tial risk of eye ...

READ MORE

More com­pa­nies need to set di­ver­si­ty en­roll­ment goals in can­cer tri­als, FDA says

4 days ago

Clin­i­cians say ben­e­fits of CAR-T con­tin­ue to out­weigh risk of T-cell ma­lig­nan­cies

5 days ago
Pharma
Cell/Gene Tx
latest in FDA+

Sen­ate Fi­nance Com­mit­tee to re­view fed­er­al poli­cies on drug short­ages

5 days ago
Law

In­tas Phar­ma­ceu­ti­cal­s' In­di­an fa­cil­i­ty hit with FDA warn­ing let­ter, placed on im­port alert

5 days ago
Manufacturing

FDA to make de­ci­sion about Karuna's schiz­o­phre­nia drug by next Sep­tem­ber

5 days ago
R&D

FDA opens re­view of CAR-T safe­ty af­ter iden­ti­fy­ing 19 cas­es of post-treat­ment blood can­cer

6 days ago
Pharma
Cell/Gene Tx

Aldeyra's dry eye drug gets a re­jec­tion from the FDA

Last week
see latest stories

Manufacturing channel feed

13 hours ago

WuXi Bi­o­log­ics’ stock slides 24% as man­u­fac­tur­ing busi­ness slows amid biotech down­turn

WuXi Bi­o­log­ics stock has plum­met­ed 24% to the low­est it's been this year af­ter the Hong Kong stock ex­change closed Mon­day morn­ing, as the man­u­fac­tur­er cites slow­er busi­ness due to ...

READ MORE

2024 VC fore­cast: Clin­i­cal-stage CD­MOs like­ly to have uptick in de­mand but spe­cial­iza­tion crit­i­cal

4 days ago

Charles Riv­er works on rare dis­ease gene ther­a­py; Emer­gent gets $75M for an­thrax vac­cine; Eu­roAPI hires new COO 

4 days ago
latest in Manufacturing

Cell man­u­fac­tur­ing com­pa­ny rais­es $19M Se­ries A to in­crease ca­pac­i­ty, staff num­bers 

4 days ago
Financing

Am­gen teams up with Ama­zon on AI plat­form to en­hance new Ohio man­u­fac­tur­ing site

5 days ago
AI

Big Phar­ma unites to help boost re­new­able en­er­gy for sup­ply chains in Chi­na and In­dia

5 days ago

RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

6 days ago
Cell/Gene Tx

US gov­ern­ment turns to more do­mes­tic phar­ma man­u­fac­tur­ing to im­prove sup­ply chain re­silience 

Last week
Pharma
see latest stories
A service from the Financial Times